Brief by Shorts91 Newsdesk / 04:06am on 21 Aug 2026,Friday Health & Wellness
Moderna’s shares surged dramatically after the US biotechnology company announced positive results from a late-stage clinical trial of its personalized melanoma vaccine, developed in partnership with Merck. The mRNA-based treatment is designed to train the immune system to recognize and attack cancer cells. The successful Phase 3 outcome marks a significant development for personalized cancer vaccines and boosted investor confidence in Moderna’s oncology pipeline. The company’s shares nearly tripled following the announcement, according to the Financial Times. However, detailed survival data and the full clinical results have not yet been publicly disclosed, meaning further regulatory review and analysis will be required.
